Login
Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

gossamerbio.com

What Do They Do?

Develops seralutinib, an inhaled drug candidate for pulmonary hypertension, including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

How Do They Make Money?

Revenue came from Chiesi through a one-time development-cost reimbursement for licenses and ongoing cost-sharing for research and development work; cost-sharing payments were tied to delivery of related services.

revenue
SegmentShareRevenue
Revenue from sale of licenses
Licensed
0.0%
Revenue from contracts with collaborators
100%

Who Are Their Customers?

Chiesi contracted with Gossamer as a seralutinib development and commercialization collaborator; the agreement later ended, and Gossamer reacquired worldwide rights.

Do Revenues Turn Into Profits?

No. It lost $170.4M in FY2025.

Operating income, FY2025
−352% of revenue
▼ −185% (Loss) vs FY2024 (−$59.9M, −52%)
Net income, FY2025
−351% of revenue
▼ −201% (Loss) vs FY2024 (−$56.5M, −49%)
Free cash flow, FY2025
−354% of revenue
▼ −4841% (Loss) vs FY2024 (−$3.5M, −3%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +189%
vs $13.3M in Q3 FY2025
Net income
▲ 0% (Loss)
vs −$48.2M in Q3 FY2025
Revenue from contracts with collaborators share of revenue vs 100.0% in Q3 FY2025
  • Jul 23, 2026 Gossamer ended Chiesi collaboration and reacquired seralutinib rights The agreement returned worldwide development and commercial rights across PAH, PH-ILD and potential future indications to Gossamer.

A narrower drug pipeline The older report described drug candidates across immunology, inflammation and oncology, including BTK programs; the latest report centers the business on seralutinib for pulmonary hypertension.

Commercial rights The older report said Gossamer retained worldwide seralutinib rights; the latest describes Chiesi holding an exclusive license to commercialize seralutinib outside the United States.

Revenue over time
Revenue from sale of licenses Revenue from contracts with collaborators
$200M$100M$0

Who Do They Compete With?

Competes with United Therapeutics, Janssen, Liquidia, Merck, Pfizer, Bayer, Gilead Sciences, Pharmosa Biopharma, Cereno Scientific, Insmed, Regeneron, 35Pharma, Novartis, Apollo Therapeutics, AllRock Bio, OrphAI Therapeutics, Pulmovant, ForeSee Pharmaceuticals, and Inhibikase Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support